Results 81 to 90 of about 436,330 (367)

Genetic attenuation of ALDH1A1 increases metastatic potential and aggressiveness in colorectal cancer

Molecular Oncology, EarlyView.
Aldehyde dehydrogenase 1A1 (ALDH1A1) is a cancer stem cell marker in several malignancies. We established a novel epithelial cell line from rectal adenocarcinoma with unique overexpression of this enzyme. Genetic attenuation of ALDH1A1 led to increased invasive capacity and metastatic potential, the inhibition of proliferation activity, and ultimately ...
Martina Poturnajova, Zuzana Kozovska, Ondrej Pos, Kristina Pavlov, Sachin Gulati, Peter Makovicky, Kristina Jakic, Monika Burikova, Eva Sedlackova, Barbora Svitkova, Silvia Tyciakova, Vojtech Bystry, Nicolas Blavet, Boris Tichy, Matej Hrnciar, Jaroslav Budis, Miroslav Tomas, Peter Dubovan, Georgina Kolnikova, Veronika Repaska, Nikoleta Mojzesova, Eva Zomborska, Daniel Pindak, Michal Mego, Tomas Szemes, Miroslava Matuskova   +25 more
wiley   +1 more source

Future therapeutic targets in rheumatoid arthritis? [PDF]

, 2017
Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by persistent joint inflammation. Without adequate treatment, patients with RA will develop joint deformity and progressive functional impairment.
A Balanescu, A Bilancio, A Del Prete, A Maas, AB Avci, AB Satterthwaite, AD Cook, AG Semb, AJ Fleetwood, AJ Fleetwood, AJ Mohamed, AL Bell, AL Cornish, AM Condliffe, AR Pettit, AW Lieshout van, B Ludewig, BF Nashed, BJ Jenkins, BZ Li, C Baerwald, C Meune, C Rommel, C Schindler, C Voigtlander, CA Martin, CJ Heijnen, CM Hilkens, CV Brenol, D Heijde van der, DH Solomon, DJ Rawlings, DL Bellinger, DM Nance, DS Lim, DT Patton, E Banham-Hall, E Clayton, E Feist, E Hirsch, E Martin, E Thomas, EB Lee, EC Tsark, EK Evans, F Berenbaum, F Bussolino, F Ramadani, FA Koopman, FA Koopman, FM Foster, G Hansen, GM Bell, GR Burmester, GR Burmester, H Evrengul, H Wang, Iain B. McInnes, IC Eijk van, IJ Elenkov, IK Campbell, J Askling, J Jang, J Kremer, JA Avina-Zubieta, JA Hamilton, JC Barrientos, JE Park, JM Kremer, JM Waldburger, JS Rawlings, JS Smolen, K Imada, K Okkenhaug, K Okkenhaug, K Okkenhaug, K Pavelka, K Reif, K Shuai, K Thiele, K Yamaoka, KL Winthrop, KP MacDonald, KS Nair, L Conti, L Jansson, L Senolt, L Zhang, L Zou, LC Cantley, LG Schipper, LJ Courtright, LV Borovikova, M Camps, M Dougados, M Field, M Gilliet, M Pesu, M Rosas-Ballina, M Skoberne, M Skoberne, M Soubrier, M Westman, MA Maanen van, MA Maanen van, MA Maanen van, MB Torchinsky, MC Genovese, MC Genovese, MC Genovese, MC Genovese, MC Genovese, MC Genovese, MC Lebre, MC Lebre, MG Roncarolo, MJ Peters, MS Ahmed, MS Thomas, N Krishnamoorthy, N Sato, NJ Gullick, P Geborek, P Norman, P Sujobert, PC Heinrich, PC Taylor, Q Yang, R Fleischmann, R Fleischmann, RA Maldonado, RF Vollenhoven van, RH Straub, RM Buijs, RM Steinman, RM Steinman, S Hayer, S Kleinau, S Mukhopadhyay, S Mukhopadhyay, S Somersan, S Tsukada, SA Provan, ST Jou, T Leizer, T Li, Tommy Tsang Cheung, TR Radstake, WJ Jonge de, WN Khan, Y Ren, Y Xu, YP Goekoop-Ruiterman, Z Li, Z Pan   +154 more
core   +1 more source

Janus kinase inhibitors - holistically seeing two faces

Australian Prescriber, 2015
Editor, - I was interested to read the recent article on Janus kinase inhibitors by Paul Kubler (Aust Prescr 2014;37:154-7). In addition to being pro-cancer, the Janus kinase-Signal Transducer and Activation of Transcription (JAK-STAT) pathway is part of a central physiological pro-survival mechanism.1 Thus pharmacological targeting of this signalling ...
John A Loudon, Paul Kubler
openaire   +2 more sources

Down‐regulation of Shh in the hair follicles of mice during chemotherapy‐induced hair loss is mediated by the JAK/STAT1 signaling pathway

FEBS Open Bio, EarlyView.
We found that during chemotherapy‐induced alopecia (CIA), Sonic hedgehog (Shh) expression significantly decreased in hair follicle Shh+ cells, whereas the Janus‐activated kinase/signal transducer and activator of transcription 1 (JAK/STAT1) signaling pathway was markedly activated.
Ruifang Fan, Jingling Huang, Xiang Lin, Tingjiao Lan, Yuli Tang, Ling Sun, Guixuan Zhou   +6 more
wiley   +1 more source

Consensus on the Clinical Approach to Moderate-to-Severe Atopic Dermatitis in Spain: A Delphi Survey [PDF]

, 2020
Background. The purpose of this study was to gather information on the current assessment and management of patients with moderate-to-severe AD in routine daily practice. Methods.
Armario Hita, José Carlos, Baldrich, Esther Serra, Herráez, L., Jáuregui, Ignacio, Martín-Santiago, Ana, Ortiz de Frutos, Javier, Sastre, Joaquin, Silvestre, Juan Francisco, Universitat Autònoma de Barcelona, Valero, Antonio   +9 more
core   +3 more sources

Temporal Trends in and Associations With Nonsteroidal Anti‐inflammatory Drug Prescription in Adult and Pediatric Patients With Inflammatory Bowel Disease

Arthritis Care &Research, EarlyView.
Objective Recent inflammatory bowel disease (IBD) treatment guidelines have recommended against nonsteroidal anti‐inflammatory drug (NSAID) use despite prevalent musculoskeletal symptoms and opioid overuse in this population. Given the discordance between changing national guidelines and potential clinical utility, we sought to assess national temporal
Adam S. Mayer, Rui Xiao, Andrew Grossman, Meenakshi Bewtra, Michael D. George, Pamela F. Weiss   +5 more
wiley   +1 more source

Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis

JK Science, 2022
Janus kinase (JAK) and signal transducer and activator of transcription (STAT) signalling has been established to have pathophysiological role in multiple disease states, such as myeloproliferative neoplasms, rheumatoid arthritis, inflammatory bowel ...
Vishal R. Tandon, Annil Mahajan
doaj  

Driving chronicity in rheumatoid arthritis: perpetuating role of myeloid cells [PDF]

, 2018
Acute inflammation is a complex and tightly regulated homeostatic process that includes leukocyte migration from the vasculature into tissues to eliminate the pathogen/injury, followed by a pro-resolving response promoting tissue repair.
Achuthan, Alivernini, Alivernini, Alvaro-Gracia, Anderson, Asquith, Bamboat, Behrens, Bell, Ben Nasr, Benham, Black, Bluml, Brentano, Burmester, Burmester, Burmester, Catrina, Cauli, Cheung, Chu, Chu, Couzin-Frankel, Cramer, Cross, den Berg, den Brand, Dillon, Donlin, Ehrenstein, Elmesmari, Ferraccioli, Field, Firestein, Frank-Bertoncelj, Gao, Ginhoux, Greven, Guiducci, Guo, Hambleton, Hamilton, Haschka, Herenius, Hogg, Hurst, Iliev, James, Jongbloed, Kaplanski, Kokkonen, Kollias, Konig, Kriegler, Kurowska-Stolarska, Kurowska-Stolarska, Kurowska-Stolarska, Lemke, Malmstrom, Mann, McInnes, McInnes, McInnes, McLoughlin, Midwood, Miller, Misharin, Misso, Moret, Moret, Morton, Murata, Na, Nagy, Nassar, Ng, O'Connell, O'Connell, O'Keeffe, Ohshima, Okada, Paolino, Park, Rajasekhar, Ramwadhdoebe, Rauber, Reynolds, Roberts, Rothlin, Rupaimoole, Rycke, Sacre, Schett, Singh, Smith, Smith, Smolen, Sokolove, Stanczyk, Steidl, Takeuchi, Tannahill, Thai, Tsoumakidou, Udalova, Vandenabeele, Villani, Watts, Weinblatt, Weiss, Williamson, Wolf, Xiong, Yeo, Yu, Zou   +115 more
core   +1 more source

Sarilumab in Polyarticular‐Course Juvenile Idiopathic Arthritis: Dose‐Finding and One‐Year Analysis of a Phase 2b, Open‐Label, Multicenter Study

Arthritis Care &Research, Accepted Article.
Objective This study assessed sarilumab in treating patients with polyarticular‐course juvenile idiopathic arthritis (pcJIA). Methods This phase 2b, open‐label study (NCT02776735) consisted of three sequential parts (each with a core‐treatment and extension‐phase). During part 1, three doses were assessed in two weight groups (Group A/B: ≥30–60 kg/≥10–<
Fabrizio De Benedetti, Inmaculada C. Penadés, Irina Nikishina, Ivan Foeldvari, Alberto J. Spindler, Anna Kozlova, Nadina Rubio‐Pérez, Pierre Quartier, Zbigniew Żuber, Raul Barria, Daniel Clemente, Gabriel V. Cornejo, Katherine Marzan, Nancy Liu, Christine Xu, Stephen DiMartino, Angeliki Giannelou, Fei Cao‐Ghoul, Bolanle Akinlade, Lydie Baret‐Cormel   +19 more
wiley   +1 more source

Potential applications of JAK inhibitors, clinically approved drugs against autoimmune diseases, in cancer therapy

Frontiers in Pharmacology
Disturbances in immunoregulation may lead to both cancer and autoimmune diseases. Many therapeutic drugs for autoimmune diseases also display anti-tumor efficacy.
Xiao-Huan Wei, Xiao-Huan Wei, Xiao-Huan Wei, Yuan-Yuan Liu, Yuan-Yuan Liu   +4 more
doaj   +1 more source